Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

84.69 +0.86 (+1.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
72 73 Next >
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again. 
Via The Motley Fool
Topics Stocks
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the... 
Via Benzinga
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial results. The drug showed similar remission rates to GSK's Nucala. 
Via Benzinga
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
From AstraZeneca
Via Business Wire
5 Oversold Stocks to Buy Right Now
We've got you covered with a list of oversold stocks to buy right now. Learn more about oversold and overbought stocks on MarketBeat. 
Via MarketBeat
AstraZeneca Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
From Virtual Investor Conferences
Via GlobeNewswire
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
From AstraZeneca
Via Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
From AstraZeneca
Via Business Wire
Moderna To Slash $1.1 Billion From R&D Spending In Major Commercial Push
The company says it's investment in R&D has paid off. Now, it needs to move its focus to launching new products. 
Via Investor's Business Daily
AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results
Chinese authorities have detained AstraZeneca employees amid a probe into potential data privacy breaches and unlicensed drug imports. CEO Pascal Soriot assures compliance with Chinese regulations and... 
Via Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to... 
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
3 Market-Beating Stocks to Buy for Less Than $100
These stocks are all up more than 20% this year. 
Via The Motley Fool
AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities
Chinese police detain AstraZeneca employees over alleged data privacy breaches and unlicensed drug imports amid an anti-corruption drive. 
Via Benzinga
Topics Law Enforcement
Reasonable Growth, Debt Levels, and a High ROIC Make ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) Appealing to Quality Investors.
Why ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) Deserves Consideration as a Quality Investment. 
Via Chartmill
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is... 
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
From AstraZeneca
Via Business Wire
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
Biotech And Life Science Sector Update Summer Of 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support
AstraZeneca may relocate its vaccine manufacturing site from Merseyside to Philadelphia as the UK government considers slashing state aid from £90 million to £40 million, jeopardizing Britain's life... 
Via Benzinga
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
A recent study in JAMA Network Open raises concerns about a potential link between GLP-1 drugs Ozempic and Wegovy and an increased rate of suicidal thoughts after analyzing World Health Organization... 
Via Benzinga
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
Johnson & Johnson to acquire V-Wave for $600 million with potential $1.1 billion in milestone payments. Deal boosts JNJ MedTech's cardiovascular portfolio. Also, FDA approves Rybrevant-Lazcluze combo... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.